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Abstract
CIB1 (calcium and integrin binding protein 1) is a small intracellular protein with numerous 
interacting partners, and hence has been implicated in various cellular functions. Recent studies 
have revealed emerging roles of CIB1 in regulating cancer cell survival and angiogenesis, although 
the mechanisms involved have remained largely undefined. In investigating the oncogenic function 
of CIB1, we initially found that CIB1 is widely up-regulated across a diverse range of cancers, 
with this up-regulation frequently correlating with oncogenic mutations of KRas. Consistent with 
this, we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated 
CIB1 expression. We previously described the Ca2+-myristoyl switch function of CIB1, and its 
ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1), 
a location where SK1 is known to elicit oncogenic signalling. Thus, we examined the role this may 
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play in oncogenesis. Consistent with these findings, we demonstrated here that over-expression of 
CIB1 by itself is sufficient to drive localisation of SK1 to the plasma membrane and enhance the 
membrane associated enzymatic activity of SK1, as well as its oncogenic signalling. We 
subsequently demonstrated that elevated levels of CIB1 resulted in full neoplastic transformation, 
in a manner dependent on SK1. In agreement with our previous findings that SK1 is a downstream 
mediator of oncogenic signalling by Ras, we found that targeting CIB1 also inhibited neoplastic 
growth of cells induced by oncogenic Ras, suggesting an important pro-tumorigenic role for CIB1. 
Thus, we have demonstrated for the first time a role for CIB1 in neoplastic transformation, and 
revealed a novel mechanism facilitating oncogenic signalling by Ras and SK1.
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Introduction
Calcium and integrin binding protein 1 (CIB1) is a Ca2+ binding protein first identified to 
interact with the αIIb cytoplasmic domain of the platelet-specific αIIbβ3 integrin1. In this 
Ca2+-dependent complex CIB1 has been proposed to play a role in platelet activation and 
aggregation2, 3. Broad tissue expression of CIB1, however, suggests roles for this protein 
outside of platelets4. Indeed, CIB1 has been found to interact with a range of other proteins, 
which have been proposed to mediate a number of non-platelet functions for this protein2.
CIB1 is a myristoylated protein and can act as Ca2+-myristoyl switch5. By analogy to 
recoverin and frequenin, the prototypical members of the Ca2+-myristoyl switch protein 
family6, in the absence of bound Ca2+ the myristoyl group is thought to be sequestered into a 
hydrophobic pocket in the protein. Upon binding Ca2+ a conformation change causes the 
extrusion of the myristoyl group from its original sheltered groove and this confers dual 
effects; firstly to enable the target proteins to interact with the now available hydrophobic 
pocket, and secondly the extruded myristoyl group targets CIB1 and any newly bound 
interacting partner to the plasma membrane6. We have recently demonstrated that, via this 
mechanism, CIB1 is essential for the agonist-induced translocation of the cancer-associated 
lipid signalling enzyme sphingosine kinase 1 (SK1) from the cytoplasm to the plasma 
membrane5. Notably, this localisation of SK1 is known to elicit oncogenic signalling7, 
raising the possibility that CIB1 may contribute to oncogenesis through regulation of SK1.
A role for CIB1 in tumor progression has been previously inferred, with reports showing its 
elevated expression in liver, breast, and pancreatic cancers8–10 and its involvement in 
enhancing cell survival, proliferation and tumour angiogenesis5, 9, 11–15. Recent studies have 
shown that depletion of CIB1 impaired triple negative breast cancer growth, leading to 
suggestions that CIB1 may represent a case of non-oncogene addiction in this form of 
cancer16. A direct role for CIB1 in inducing neoplastic transformation has, however, not 
been previously examined. Here, we show for the first time that CIB1 can directly induce 
full neoplastic transformation of cells in a manner highly dependent on SK1. We also show 
that CIB1 is up-regulated in a wide range of human cancers, and provide evidence indicating 
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this may be both a consequence of the common hyperactivation of the Ras-ERK pathway, 
and an important mediator of Ras-induced oncogenesis.
Results and Discussion
CIB1 is widely over-expressed in human cancers and correlates with oncogenic Ras 
mutation
To initially investigate the role of CIB1 in oncogenesis we examined its expression in human 
cancers using the public gene expression datasets in the Oncomine database17. CIB1 has 
been previously found to be elevated in some liver, breast and pancreatic cancers8–10, but a 
broad analysis of CIB1 expression in cancer has not been previously performed. Strikingly, 
we found that CIB1 was widely up-regulated in a broad array of cancer types, compared to 
their corresponding normal tissues (Figure 1A, S1). This includes a range of breast and 
ovarian cancer subtypes, lung adenocarcinoma, some leukaemias, and an array of 
gastrointestinal tumours. To confirm these findings we examined CIB1 protein expression in 
human tissues of several tumour types. Immunohistochemical (IHC) analysis of a panel of 
35 human colorectal cancer tissues revealed significant upregulation of CIB1 in tumours 
compared to normal colorectal tissue matched from the same patients (Figure 1B). A similar 
elevation of CIB1 protein was also found in invasive ductal breast carcinoma and lung 
adenocarcinoma tissues by IHC (Figures 1C and S2A,B), and in acute myeloid leukaemia by 
immunoblot analysis of patient bone marrow biopsies (Figure 1D, S2C).
In light of this upregulation of CIB1 in multiple cancer types, we performed Kaplan Meier 
analysis on publically available cancer datasets18, 19. Similar to a previous report with liver 
cancer patients8, a significant correlation between elevated CIB1 expression and poorer 
prognosis was evident in patients with estrogen receptor negative breast cancer and lung 
adenocarcinoma (Figure S2D). The high expression of CIB1 in multiple cancers prompted 
us to examine a correlation between the presence of common oncogenes and CIB1 
expression. Initial analysis of the Garnett human multicancer cell line gene expression 
dataset20 found a highly significant correlation between high CIB1 expression and a number 
of oncogenic mutations, the most significant being oncogenic KRas mutations (Table S1). 
Activating mutations in the Ras genes (K-, H- and NRas) are found in around 16% of all 
human cancers, making it one of the most commonly mutated gene families in cancer21. 
This is particularly the case in colorectal cancer, where a third of tumours harbour oncogenic 
KRas mutations21. Since CIB1 was also up-regulated in colon cancer (Figure 1A,B), we 
then examined the public datasets detailing matched gene mutation and expression analysis 
for cancers of this type within The Cancer Genome Atlas (TCGA) resource. Strikingly, 
analysis of the colorectal adenocarcinoma datasets22 showed a significant positive 
correlation between the presence of oncogenic KRas mutations and elevated CIB1 
expression (Figure 1E). IHC analysis of CIB1 in human colorectal tissues with known KRas 
mutation status also confirmed a similar correlation at the protein level (Figure 1F). By 
further mining the Oncomine database, we also found higher CIB1 expression in KRas 
mutated patients of lung adenocarcinoma and acute myeloid leukaemia (AML), where KRas 
mutation is less common (Figure 1G). These observations together suggested a potential role 
for Ras mutation to mediate enhanced CIB1 expression. Thus, we next directly examined the 
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effect of expression of oncogenic Ras on endogenous CIB1 expression in HEK293 cells, 
which endogenously possess only wildtype Ras23. Notably, ectopic expression of oncogenic 
KRas or HRas in these cells resulted in a significant upregulation of CIB1 mRNA and 
protein compared to vector control cells (Figure 1H, I), to a comparable extent to that seen in 
the human cancer analysis (Figure 1A–G).
Although the mechanisms of transcriptional regulation of CIB1 remain unknown, our 
findings suggested that transcription factors downstream of the Ras/MAPK pathway are 
likely to be involved. Indeed, analysis using the UCSC Genome Browser24, 25 revealed 
binding sites in the 5′ proximal region of the CIB1 gene for c-Fos and c-Myc, two common 
Ras effectors26, 27, supporting this hypothesis.
CIB1 induces oncogenic signalling by SK1
Since we had established up-regulation of CIB1 expression in multiple human cancers we 
next investigated the oncogenic potential of CIB1 by initially examining the effect of its 
over-expression on cell proliferation. Consistent with previous studies that have shown 
reduction in cell survival and proliferation in response to RNAi knockdown or genetic 
ablation of CIB1 expression5, 13, 15, 16, 28, over-expression of CIB1 resulted in a significant 
increase in the cellular growth rate in both low and higher serum culture conditions, and also 
supported some serum-independent cell growth, compared to vector control cells (Figure 
2A).
While previous studies had implicated a partial role for PAK1 in CIB1-mediated cancer cell 
survival 16, the main mediator(s) of this effect remained unclear. Since CIB1 has an 
established role in agonist-induced translocation of SK1 from the cytoplasm to the plasma 
membrane5, and this localisation of SK1 is known to enhance cell proliferation and 
survival7, we investigated whether CIB1 over-expression itself could induce plasma 
membrane localisation of SK1. Fluorescence microscopy showed that overexpression of 
CIB1 induced an increase in SK1 protein localised to the plasma membrane (Figures 2B,C, 
S3A), which was supported by elevated plasma membrane-associated SK1 catalytic activity 
(Figure 2D), and enhanced intracellular and extracellular S1P generation (Figure 2E) in 
CIB1 overexpressing cells. This CIB1-induced elevation of S1P was blocked by inhibition of 
SK1 with the isoform-selective SK1 inhibitor, SK1-I29 (Figure S3B), confirming this effect 
was dependent on SK1. Notably, consistent with the importance of the Ca2+-myristoyl 
switch function of CIB15, this altered localisation of SK1 was dependent on CIB1 
myristoylation since introduction of an alanine at the myristoylation site (CIB1G2A) to block 
CIB1 myristoylation completely prevented the redistribution of SK1 to the plasma 
membrane (Figure 2B–D, S3A) and subsequent elevation of intracellular and extracellular 
S1P (Figure 2E). Importantly, we confirmed that this non-myristoylated CIB1G2A variant 
retained its Ca2+-dependent interaction with SK1 (Figure S3C).
Our previous studies demonstrated an important role for phosphorylation of SK1 at Ser225 
in translocation of SK1 from the cytoplasm to the plasma membrane in response to cell 
agonists like tumour necrosis factor-α7. Other studies by Obeid and colleagues30, however, 
showed sustained activation of the Ras/MAPK pathway through oncogenic KRas expression 
could induce plasma membrane localisation of SK1 in a manner independent of SK1 
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phosphorylation at Ser225. The mechanisms facilitating this sustained plasma membrane 
localisation, however, were not defined. Notably, our observations that CIB1 is up-regulated 
by Ras (Figure 1H,I), together with our data demonstrating that CIB1 over-expression alone 
can drive plasma membrane localisation of SK1 (Figure 2B,C), now provides a likely 
mechanism for these previous observations. To interrogate this, we examined the effect of 
oncogenic Ras on the localisation of SK1 and the non-phosphorylatable SK1S225A in 
wildtype and CIB1−/− mouse embryonic fibroblasts (MEFs). Consistent with the previous 
findings30, in wildtype MEFs oncogenic Ras induced plasma membrane localisation of both 
SK1 and SK1S225A (Figures 2F,G, S3D). In CIB1−/− MEFs, however, this oncogenic Ras-
induced relocalisation of SK1 was not observed (Figure 2F,G, S3D), consistent with a 
critical role for CIB1 in this process. Notably, the structural basis for the S225 
phosphorylation-independent association of SK1 with CIB1 has been recently proposed by 
Adams et al.31 to potentially involve flexibility in helix-α8 of SK1, which we have 
previously implicated in CIB1 binding5.
Since both CIB1 and SK1 appear elevated in a wide range of cancers, we next investigated 
whether these two genes display co-ordinate regulation in human cancers. Gene expression 
analysis, however, showed that SK1 was rarely elevated in the cancer cohorts where 
significantly increased CIB1 expression was observed (Figure S4A). We also found no clear 
association between CIB1 and SK1 expression in lung adenocarcinoma patients with KRas 
mutations (Figure S4B). Furthermore, ectopic expression of CIB1 in HEK293 cells showed 
no effect on endogenous SK1 mRNA nor protein (Figure S4C,D), further suggesting that 
CIB1 is more likely to enhance SK1 signalling through altering its sub-cellular localisation, 
rather than expression.
CIB1 induces neoplastic transformation in a SK1-dependent manner
Next we investigated whether expression of CIB1 had the ability to induce neoplastic 
transformation of cells. Focus formation assays with NIH3T3 fibroblasts (Figure 3A) 
showed that cells over-expressing CIB1 induced numerous foci, indicating loss of contact 
inhibition in these cells consistent with neoplastic transformation. In stark contrast, cells 
expressing the non-myristoylated CIB1G2A did not generate foci, again demonstrating the 
importance of this modification for the oncogenic function of CIB1. To confirm that the 
CIB1 over-expressing cells had undergone full neoplastic transformation we next performed 
subcutaneous xenografts of the cells into the flanks of NOD/SCID mice. Consistent with the 
in vitro focus formation assays, tumours formed in all five mice injected with cells over-
expressing CIB1, while no tumours were evident in either vector or CIB1G2A expressing 
cells (Figure 3B). Thus, these findings indicate CIB1 can directly induce full neoplastic 
transformation in a manner dependent on its myristoylation, again consistent with the 
importance of the Ca2+-myristoyl switch function of this protein.
To determine the dependence on SK1 for the CIB1-induced neoplastic transformation we 
examined the effect of a range of SK inhibitors on neoplastic growth of the CIB1 over-
expressing cells. Strikingly, the SK1-selective inhibitor SK1-I, as well as the pan-SK 
inhibitors MP-A08 32 and SKI-II 33 all effectively blocked CIB1-induced neoplastic growth 
in both focus formation (Figure 3C) and soft agar colony formation assays (Figure S5A), 
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consistent with an important role for SK1 in this process. To further confirm the role of SK1 
we next examined the ability of CIB1 to induce neoplastic transformation in immortalised 
SK1 knockout (SK1−/−) MEFs. Consistent with our observations in NIH3T3 cells, CIB1 
induced neoplastic transformation in MEFs from wildtype mice, as assessed by focus 
formation assays (Figure 3D). No such neoplastic growth was observed, however, in MEFs 
from SK1−/− mice clearly showing a requirement for SK1 in CIB-induced neoplastic 
transformation. Together these findings, for the first time, define a molecular mechanism for 
the role of CIB1 in cancer through its regulation of SK1.
Ablating CIB1 expression attenuates Ras-induced neoplastic transformation
SK1 has been previously shown to have a role in oncogenic signalling by Ras since chemical 
inhibitors of SK or a dominant-negative SK1 attenuated Ras-induced neoplastic 
transformation34, 35. To further validate these findings we examined the ability of Ras to 
induce neoplastic transformation of immortalised SK1−/− MEFs. Focus formation assays 
showed that oncogenic Ras failed to induce neoplastic transformation in these cells lacking 
SK1, consistent with an essential role for SK1 in oncogenic signalling by Ras (Figure 4A).
To investigate whether the CIB1-mediated SK1 translocation is specifically involved in 
oncogenesis by Ras, we examined immortalised CIB1−/− MEFs, where we had shown 
deficiency in Ras-induced plasma membrane localisation of SK1 (Figure 2F,G). Compared 
to wildtype MEFs, significant attenuation of Ras-induced neoplastic transformation was 
observed in these CIB1−/− cells (Figure 4B, S5B). To further validate these findings, we also 
examined the effect of the non-myristoylated CIB1G2A, which we found to block 
localisation of SK1 to the plasma membrane (Figure 2B, C)5, on Ras-induced transformation 
of NIH3T3 cells. As expected, oncogenic Ras induced efficient neoplastic transformation of 
these cells, as assessed by focus formation and colony formation assays (Figures 4C and 
S5C). Consistent with our earlier findings, over-expression of wildtype CIB1 alone also 
induced neoplastic transformation, which was not further enhanced by oncogenic Ras. Cells 
expressing CIB1G2A were, however, remarkably resistant to Ras induced neoplastic 
transformation in both focus formation (Figure 4C) and colony formation assays (Figure 
S5C). Notably, while previous studies have suggested that loss of CIB1 expression 
attenuates ERK1/2 activation15, 16, 36, our analysis of this pathway found no effect on the 
levels of phospho-ERK1/2 in the basal state or in response to oncogenic Ras by the 
overexpression of either wildtype or CIB1G2A (Figure 4D). Thus, these observations are 
consistent with the notion that the effects of attenuated Ras-induced neoplastic signalling by 
CIB1G2A occur downstream of ERK1/2, at the level of SK1.
Conclusions
A major novel finding of this study is the identification of CIB1 as an important effector of 
oncogenic signalling by Ras through the enhancement of subcellular localisation of SK1 to 
the plasma membrane. An oncogenic role for SK1 has been well-established in a variety of 
cancers37–39, and we have previously elucidated that plasma membrane localisation of the 
enzyme is critical for its oncogenic signalling function7. Notably, in these previous studies 
we described a mechanism whereby phosphorylation of SK1 induces its plasma membrane 
localisation and subsequent oncogenic signalling7, 40, 41. The current studies, however, 
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demonstrate that an alternative, phosphorylation-independent mechanism driving plasma 
membrane localisation and subsequent oncogenic signalling by SK1 can also exist involving 
CIB1. The fact that this regulation of SK1 is mediated by enhanced expression of CIB1 in 
response to oncogenic Ras mutations, combined with the high frequency of these Ras 
mutation in human cancer21, suggest that these findings may have broad implications for 
many cancers. Thus, overall, these findings indicate that CIB1 represents a promising target 
for modulating Ras and SK1 signalling outcomes in cancer, warranting further investigation 
of the CIB1-SK1 interaction for the development of novel cancer therapeutics.
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Figure 1. CIB1 expression is elevated in multiple cancers and is associated with oncogenic Ras 
mutation
(A) Gene expression datasets from the Oncomine database17 were mined for CIB1 
expression in normal compared to cancer tissues. The heat map shows all the datasets with 
significant elevated levels of CIB1 in cancer tissues (p<0.0001). Each row represents a 
cancer subtype from an individual dataset. Further detail is presented in Figure S1. (B) 
Paired histology sections from tumours excised from 35 colorectal cancer patients were 
assessed for levels of CIB1 protein by immunohistochemistry analysis. Custom made tissue 
microarrays (TMAs) were used with no less than two representative cores of tumour tissue 
and matched non-neoplastic colonic mucosa being inserted into the recipient TMA block. 
Sections (4 μm) of paraffin wax-embedded tissue were mounted on coated slides, dewaxed, 
and rehydrated using standard techniques. Antigen retrieval was performed with the 
microwave using 10 mM citrate buffer (pH 6), by bringing it to a boil on high heat, and then 
simmering for 15 min. After cooling to 40°C, the sections were incubated for 60 min at 
room temperature with mouse anti-human primary CIB1 monoclonal antibody (1:250 
dilution; R&D Systems). The ADVANCE™ kit (Dako) employing DAB as the detection 
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system was used. Immunostaining was performed on the DAKO Autostainer Plus platform. 
Counterstaining was performed using Mayer’s hematoxylin. Samples were scored as either 
strongly positive (++), weakly positive (+) if heterogeneous staining was detected in cell 
cytoplasm, or negative if there was no staining present. A negative control was performed by 
omitting the primary antibody. ****p<0.0001. NC: normal crypt; CRC: colorectal cancer. 
Samples were obtained with informed consent from patients diagnosed with colorectal 
adenocarcinoma according to institutional guidelines and studies were approved by the 
Royal Adelaide Hospital Human Research Ethics Committee. (C) Commercial breast and 
lung TMAs containing two representative cores of tumour or normal tissues (Protein 
Biotechnologies) were used to examine the level of CIB1 expression by IHC analysis. 
Results show average scores of CIB1 staining in normal breast (n = 16), invasive ductal 
breast carcinoma (n = 69), normal lung (n = 20), and lung adenocarcinoma (n = 31) tissues. 
Only tissues with valid staining in both duplicate cores were scored. *p<0.05. (D) 
Diagnostic bone marrow or apheresis product samples were obtained with informed consent 
from patients diagnosed with AML or health volunteers according to institutional guidelines. 
Studies were approved by the Royal Adelaide Hospital Human Research Ethics Committee. 
Mononuclear cells were isolated by Ficoll-Hypaque density-gradient centrifugation and 
resuspended in IMDM containing 0.5% foetal calf serum (FCS). Morphological analysis 
revealed >80% AML blasts post centrifugation. Cell lysates from bone marrows of 11 AML 
patients and 4 healthy donors were resolved by SDS-PAGE and immunoblot analysis using 
anti-CIB1 and anti-actin antibodies (both from Millipore) as previously described42. 
Densitometry of the CIB1 and tubulin bands was quantified using the Image Studio™ Lite 
software (LI-COR). *p<0.05. (E) TCGA colorectal cancer (COADREAD) dataset were 
mined for the level of CIB1 expression in cancerous tissues with or without KRas mutations. 
CIB1 expression data (exon expression, Illumina HiSeq) and COADREAD clinical data 
were obtained from the UCSC Cancer Genome browser (https://genome-cancer.ucsc.edu/
proj/site/hgHeatmap; dataset ID: TCGA_COADREAD_exp_HiSeqV2_exon). *p<0.05. (F) 
Custom made TMAs containing 31 colorectal cancerous tissues with wild type KRas and 30 
with known KRas somatic mutation were examined for level of CIB1 expression by IHC. To 
screen for mutations of the KRas gene, DNA was prepared from cancer tissue macro-
dissected from formalin fixed, paraffin embedded (FFPE) slides using the QIAamp DNA 
FFPE Tissue Kit (Qiagen, Valencia, CA) and a multiplex assay was performed to screen for 
mutations in codons 12 and 13 of the KRAS gene43. Only tissues with valid staining in both 
duplicate cores were scored. *p<0.05. (G) Oncomine datasets were mined for the level of 
CIB1 expression in cancerous tissues with or without KRas mutations. Oncomine data for 
lung adenocarcinoma (Okayama lung) and acute myeloid leukaemia (Raponi leukaemia) are 
shown. *p<0.05; **p<0.01. (H) HEK293 cells were transiently transfected with oncogenic 
HRasG12V or GFP tagged KRasG12V. The gene expression of CIB1 was measured by 
quantitative RT-PCR using SYBR green PCR master mix (QIAGEN) and the primers 
AGTACCAGGACTTGACGTTCC (forward) and CTTGAGCTCTGGAAGGCTGA 
(reverse). The PCR thermocycling conditions were 50 °C for 2 min, 95 °C for 15 min, 
followed by 40 cycles of 95 °C for 15 s, 60 °C for 33 s, and 72 °C for 33 s. The 
housekeeping gene GAPDH was measured by primers ACCCAGAAGACTGTGGATGG 
(forward) and CAGTGAGCTTCCCGTTCAG (reverse). The relative gene expression of 
CIB1 normalised to relative gene expression GAPDH was analysed using the comparative 
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quantitation method using the Rotor-Gene Q Series software. Data shows mean ± SEM of 
three independent experiments. **p<0.01; **** p<0.0001. (I) Lysates of HEK293 cells 
ectopically expressing HRasG12V or GFP tagged KRasG12V were analysed by immunoblot 
using anti-CIB1, anti-Ras (both from Millipore), and anti-tubulin antibodies (Abcam). 
Densitometry of the CIB1 and tubulin bands was performed using the Image Studio™ Lite 
software (LI-COR). Data shows mean ± SEM of relative CIB1 expression normalised to 
vector control from three independent experiments. *p<0.05. pCXbla (Vector) and pCXbla-
HRasG12V plasmids were generated as follows. The blasticidin (bla) resistance gene was 
amplified from pLenti6/TR (Invitrogen) with the following oligonucleotides 5′-
TGCATCTCAATTAGTCAGCAA-3′ and 5′-TAGAATT 
CTTCGAATTAGCCCTCCCACACATAAC-3′, digested with XmaI and EcoRI and cloned 
into pGEM4Z (Promega). The XmaI/BstBI cassette from pGEM4Z-bla was used to replace 
the neomycin (neo) resistance gene in pCXneo-IRES-EGFP digested with XmaI/BstBI to 
produce pCXbla-IRES EGFP. Digestion of pCXbla-IRES-EGFP with SacI/XhoI and 
subsequent blunting, re-ligation produced pCXbla. HRasG12V was PCR amplified from 
pSG5V12Ras, a kind gift from J. Downward44, with the following oligonucleotides 5′-
TAGAATTCGCCACC ATGACCGAATACAAGCTTGTTG-3′ and 5′-
TAGAATTCTCAGGAGAGCA CACACTTGC-3′, digested with EcoRI and cloned into 
pCXbla. Sequencing verified integrity and orientation of all the cDNA’s. GFP-KRas1bG12V 
was a kind gift from R. Parton45. HEK293 cells were originally obtained from American 
Type Culture Collection (ATCC), cultured for fewer than 6 months after resuscitation as 
previously described5 and transfected using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s protocol. Statistical analysis was performed with non-parametric two-
tailed Mann-Whitney tests for the data shown in panels B–G and two tailed unpaired t tests 
for data in panels H and I.
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Figure 2. Over-expression of CIB1 promotes translocation of SK1 to the plasma membrane
(A) Proliferation of NIH3T3 cells stably transfected with CIB1 (●) or vector control (○) in 
serum free or low serum conditions (1% and 5% FCS) were measured in quadruplicate by 
MTS assays (Promega) according to manufacturer’s protocol. Data shows mean ± SD; 
representative of three independent experiments. ****p<0.0001. (B) HeLa cells over-
expressing HA-tagged CIB1, CIB1G2A (Ref. 5), or vector control were stimulated with 
phorbol 12-myristate 13-acetate and visualised by fluorescence microscopy, as previously 
described5. SK1 was visualised via its EGFP tag (green)40 and CIB1 via 
immunofluorescence staining of its HA epitope tag (red) using anti-HA antibodies (Cell 
Signaling). Over 350 cells were visualised (B) and quantitated (C) from each of three 
independent experiments. **p<0.01. (D) Lysates of NIH3T3 cells over-expressing CIB1, 
CIB1G2A, or vector control were subjected to sub-cellular fractionation as previously 
described40. SK1 in the membrane and cytosolic fractions were assessed by SK1 activity 
assays under conditions largely specific for SK146, and expressed as a ratio of membrane to 
cytosol. Total SK1 activity in whole cell lysates showed no significant difference between 
groups. Data shows mean ± SEM; n=3. *p<0.05, ** p<0.01. (E) S1P generation in NIH3T3 
cells over-expressing CIB1, CIB1G2A, or vector control was assessed by metabolically 
labelling the cells with 3H-sphingosine, as described previously32. Radiolabelled 
intracellular and extracellular S1P were measured by scintillation counting. Data shows 
mean ± SEM; n = 3, ** p<0.01; *** p<0.001. (F) Wild type or CIB1−/− MEFs were 
transfected with vectors encoding EGFP-tagged SK1 or SK1S225A (Ref. 40) and effects on 
subcellular localisation assessed by confocal microscopy with or without co-transfection 
with a vector encoding oncogenic HRasG12V. Localisation of SK1 and SK1S225A were 
visualised by their EGFP fusions (green) and Ras was visualised via anti-Ras 
immunofluorescence staining (red). Due to low transfection efficiency of MEF cells, 
between 100–200 cells were visualised (F) and quantitated (G) from each of three 
independent experiments. **p<0.01. HeLa and NIH3T3 cells were obtained from the ATCC, 
cultured for fewer than 6 months after resuscitation, and transfected as previously 
described5, 7, MEFs were generated from wild type, SK1−/− and CIB1−/− mouse11, 47 
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embryos at 14.5 days post coitum. The cells were cultured in a humidified atmosphere with 
10% CO2. Passage one MEFs were immortalized by transfection with a plasmid encoding 
the SV40 large T antigen using Nucleofection (Lonza), with stable transfectants selected by 
zeocin resistance. Statistical analysis was performed with two-way analysis of variance 
(ANOVA) for the data in panel A and two tailed unpaired t tests for the data in panels C–E 
and G.
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Figure 3. CIB1 promotes neoplastic transformation in a manner dependent on SK1
(A) NIH3T3 cells stably transfected with CIB1, CIB1G2A or vector control were assessed for 
neoplastic growth by focus formation assays, as described previously35. Data shows mean ± 
SD; representative of three independent experiments. **p<0.01. Cells expressing CIB1G2A 
remained viable but did not form obvious foci. (B) NIH3T3 cells stably transfected with 
vectors encoding CIB1, CIB1G2A or empty vector control were assessed for their ability to 
form tumours when subcutaneously injected into the flank of NOD/SCID mice. Seven week 
old female NOD-SCID mice were obtained from the Animal Resources Centre, Western 
Australia, and housed in sterile micro-isolator cages and provided with sterile food and 
water and treated following the conditions approved by the Institutional Animal Ethics 
Committee. Stably transfected NIH3T3 cells (1 x 106/mouse) resuspended in sterile PBS 
were subcutaneously injected into the flanks of five mice/cell line. Mice were monitored 
daily for tumour growth, humanely killed 3 weeks post-injection, and tumours excised, 
weighed, and then analysed by immunoblot with HA antibodies to confirm CIB1 expression. 
(C) NIH3T3 cells stably transfected with CIB1 were assessed for neoplastic growth by focus 
formation assays in the presence of vehicle alone or SK1 inhibitors SKI-II (5μM), MP-A08 
(20μM) or SK1-I (5 μM). Data shows mean ± SD; representative of three independent 
experiments. *p< 0.05; **p<0.01. (D) Wild type or SK1−/− MEFs over-expressing CIB1 
were assessed for neoplastic transformation by focus formation assays. Data shows mean ± 
SD; representative of three independent experiments. ****p<0.0001. To generate cell lines 
stably expressing CIB1, pCXneo-IRES-EGFP and pCXneo-CIB1(HA)-IRES-EGFP were 
generated as described below. pCX-EGFP was a kind gift from M. Okabe48. EGFP was 
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replaced with a polylinker following digestion with EcoRI and ligation of annealed kinased 
oligonucleotides 5′-AATTCGGTACCGAG CTCGCTAGCGCGGCCGCCTCGAGC-3′ and 
5′-AATTGCTCGAGGCGGCCG CGCTAGCGAGCTCGGTACCG-3′ to produce pCX4. A 
blunted SalI and EcoRI cassette from pCX4 encompassing the chicken β-actin promoter was 
used to replace the CMV promoter of pcDNA3-IRES-EGFP following blunted BglII and 
EcoRI digestion to produce pCXneo-IRES-EGFP. pCXneo-CIB1(HA)-IRES-EGFP was 
produced by cloning with EcoRI. NIH3T3 cells transfected with these CIB1 constructs were 
selected for G418 resistance and then sorted for high GFP expression using a Becton 
Dickinson FACS Aria (BD Biosciences). Statistical analysis was performed with two tailed 
unpaired t tests.
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Figure 4. CIB1 is an effector of oncogenic Ras signalling
(A) Wild type or SK1−/− MEFs were stably transfected with pSG5V12Ras (for expression of 
HRasG12V)or vector control and assessed for neoplastic transformation by focus formation 
assays as described above. (B) Wild type and CIB1−/− MEFs were stably transfected with 
pCXbla-HRasG12V, which was sub-cloned from pSG5V12Ras as described above. Due to the 
potent expression of HRasG12V by pCXbla-HRasG12V which contains a more potent Kozak 
sequence, the stable transfectants were diluted 1:1000 with their corresponding parental 
MEF lines to enable visualisation and quantification of oncogenic Ras-induced foci. For (A) 
data shows mean ± SD; representative of three independent experiments. ***p<0.001; and 
(B) data shows mean ± SEM; n = 6. ***p<0.001. (C) NIH3T3 cells stably expressing CIB1, 
CIB1G2A, or vector control were transiently transfected with HRasG12V and applied to focus 
formation assays. Data shows mean ± SEM; n = 3. *p<0.05, ** p<0.01. (D) NIH3T3 cells 
over-expressing CIB1, CIB1G2A were co-transfected with or without HRasG12V. The level 
of pERK1/2, ERK1/2, Ras, and HA tagged CIB1 in these cells were analysed by 
immunoblotting using antibodies from Cell Signaling, Promega, Millipore and Sigma-
Aldrich, respectively. Results are representative of three independent experiments. Statistical 
analysis was performed with two tailed unpaired t tests.
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